Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Fatty acids are essential for survival, acting as bioenergetic substrates, structural
components and signalling molecules. Given their vital role, cells have evolved mechanisms …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …

Bile acids (BAs) can regulate their own metabolism and transport as well as other key
aspects of metabolic homeostasis via dedicated (nuclear and G protein-coupled) receptors …

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Non‐alcoholic fatty liver disease (NAFLD) comprises a wide spectrum of pathologies
ranging from non‐alcoholic fatty liver (NAFL), characterized by simple steatosis without …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Background & Aims Non-alcoholic steatohepatitis (NASH) is associated with increased risk
of liver-related and cardiovascular morbidity and mortality. Given the complex …